Literature DB >> 19296419

Streptococcus pneumoniae: epidemiology, risk factors, and strategies for prevention.

Joseph P Lynch1, George G Zhanel.   

Abstract

Streptococcus pneumoniae is the most common cause of community-acquired pneumonia, meningitis, and bacteremia in children and adults. Invasive pneumococcal disease (IPD) primarily affects young children, older adults (> 65 years of age), and individuals with comorbidities or impaired immune systems. Case fatality rates range from 10 to 30% in adults with IPD but are much lower (< 3%) in children. In this article, we describe the epidemiology of IPD, risk factors, and the influence of host- and organism-specific factors on outcomes. Most cases of IPD are caused by a limited number of serotypes that vary in infectivity and virulence. Vaccinating adults and high-risk patients with the pneumococcal polysaccharide vaccine reduces the incidence of IPD in populations at risk but does not affect nasopharyngeal colonization and has had limited benefit in the population at large. Use of the heptavalent pneumococcal conjugate vaccine (PCV7) in children in the United States since 2000 has resulted in a substantial decline of IPD in both children and adults (by herd immunity), but has facilitated the emergence of serotypes not encompassed in the PCV7 vaccine. Recent reports of "replacement" serotypes that have heightened virulence are worrisome. In this chapter, we discuss the role of vaccines (both polysaccharide and conjugate) and other preventive strategies to limit this important and potentially lethal disease.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19296419     DOI: 10.1055/s-0029-1202938

Source DB:  PubMed          Journal:  Semin Respir Crit Care Med        ISSN: 1069-3424            Impact factor:   3.119


  76 in total

Review 1.  Pneumococci: immunology of the innate host response.

Authors:  Gavin K Paterson; Carlos J Orihuela
Journal:  Respirology       Date:  2010-07-20       Impact factor: 6.424

2.  Serotype-independent protection against pneumococcal infections elicited by intranasal immunization with ethanol-killed pneumococcal strain, SPY1.

Authors:  Xiuyu Xu; Jiangping Meng; Yiping Wang; Jie Zheng; Kaifeng Wu; Xuemei Zhang; Yibing Yin; Qun Zhang
Journal:  J Microbiol       Date:  2014-03-29       Impact factor: 3.422

3.  Serotype distribution and antimicrobial resistance of Streptococcus pneumoniae prior to introduction of the 10-valent pneumococcal conjugate vaccine in Brazil, 2000-2007.

Authors:  Ana Paula de O Menezes; Leila C Campos; Milena S dos Santos; Jailton Azevedo; Renan C N Dos Santos; Maria da Gloria S Carvalho; Bernard W Beall; Stacey W Martin; Katia Salgado; Mitermayer G Reis; Albert I Ko; Joice N Reis
Journal:  Vaccine       Date:  2010-12-21       Impact factor: 3.641

4.  Chitinase 3-like-1 promotes Streptococcus pneumoniae killing and augments host tolerance to lung antibacterial responses.

Authors:  Charles S Dela Cruz; Wei Liu; Chuan Hua He; Adam Jacoby; Alex Gornitzky; Bing Ma; Richard Flavell; Chun Geun Lee; Jack A Elias
Journal:  Cell Host Microbe       Date:  2012-07-19       Impact factor: 21.023

Review 5.  The role of vaccination in preventing pneumococcal disease in adults.

Authors:  S Aliberti; M Mantero; M Mirsaeidi; F Blasi
Journal:  Clin Microbiol Infect       Date:  2014-02-22       Impact factor: 8.067

6.  Prevalence of PspA families and pilus islets among Streptococcus pneumoniae colonizing children before and after universal use of pneumococcal conjugate vaccines in Brazil.

Authors:  Patricia Alice Knupp-Pereira; Nayara Torres Cardoso Marques; Lúcia Martins Teixeira; Helvécio Cardoso Corrêa Póvoa; Felipe Piedade Gonçalves Neves
Journal:  Braz J Microbiol       Date:  2019-12-04       Impact factor: 2.476

7.  Role of phosphoinositide 3-kinase-Akt signaling pathway in the age-related cytokine dysregulation in splenic macrophages stimulated via TLR-2 or TLR-4 receptors.

Authors:  Mosoka P Fallah; R Lakshman Chelvarajan; Beth A Garvy; Subbarao Bondada
Journal:  Mech Ageing Dev       Date:  2011-05-27       Impact factor: 5.432

8.  Long-term trends in invasive pneumococcal disease in Manitoba, Canada.

Authors:  Salaheddin M Mahmud; Hasantha Sinnock; Luiz C Mostaço-Guidolin; Gurpreet Pabla; Aleksandra K Wierzbowski; Songul Bozat-Emre
Journal:  Hum Vaccin Immunother       Date:  2017-05-11       Impact factor: 3.452

9.  Targeting inflammatory monocytes in sepsis-associated encephalopathy and long-term cognitive impairment.

Authors:  Graciela Andonegui; Erin L Zelinski; Courtney L Schubert; Derrice Knight; Laura A Craig; Brent W Winston; Simon C Spanswick; Björn Petri; Craig N Jenne; Janice C Sutherland; Rita Nguyen; Natalie Jayawardena; Margaret M Kelly; Christopher J Doig; Robert J Sutherland; Paul Kubes
Journal:  JCI Insight       Date:  2018-05-03

10.  Administration of a probiotic associated with nasal vaccination with inactivated Lactococcus lactis-PppA induces effective protection against pneumoccocal infection in young mice.

Authors:  E Vintiñi; J Villena; S Alvarez; M Medina
Journal:  Clin Exp Immunol       Date:  2009-12-04       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.